Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences Inc (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company pioneering therapies targeting lipid-signaling pathways, including innovative approaches to cancer support care and neuropathic pain management. This page provides investors and researchers with verified updates on the company’s progress in developing novel treatments for conditions with high unmet medical needs.
Access comprehensive coverage of clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection includes press releases about Artelo’s proprietary cocrystal technology, FABP5 inhibitor program, and advancements in cannabinoid-based therapeutics – all essential for tracking the company’s pipeline evolution.
Stay informed about critical updates including Phase trial results, intellectual property filings, and collaborations with global research institutions. Bookmark this page for real-time insights into how Artelo Biosciences is advancing treatments for chemotherapy-induced neuropathy, cancer-related anorexia, and inflammatory conditions through cutting-edge science.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the virtual H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. Key executives, including Andy Yates and Prof. Saoirse O’Sullivan, will engage in a panel discussing the endocannabinoid system on January 11 at 3:00 PM ET. Additionally, Gregory Gorgas, CEO, will present the company's outlook on January 10, available on-demand to attendees. The conference will spotlight Artelo's development of therapeutics targeting significant health issues, including anorexia and cancer.
Artelo Biosciences (Nasdaq: ARTL) reported financial results for the fiscal year ending August 31, 2021, highlighting a strong balance sheet with over $26.8 million in cash and marketable securities as of November 15, 2021. The company is focused on advancing its lead therapeutic, ART27.13, designed to combat cancer-related anorexia, with Phase 1 data expected in Q1 2022 and Phase 2 data later in the year. Despite a net loss of approximately $7.4 million for 2021, operational progress and clinical trials remain key priorities.
Artelo Biosciences (NASDAQ: ARTL) announced that its CEO, Gregory Gorgas, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on demand for registered attendees starting September 13 at 7:00 AM ET. Artelo aims to develop therapeutics targeting lipid signaling pathways, focusing on unmet medical needs in areas such as cancer and pain management. For more details, the company's presentation can be accessed via its investor relations webpage.
Artelo Biosciences (ARTL) announced findings published in Medical Cannabis and Cannabinoids showing no significant pharmacological differences between natural and synthetic CBD in antiproliferative, anti-inflammatory, or permeability effects. CEO Gregory D. Gorgas emphasized that biopharmaceutical properties are key differentiators for CBD products. Artelo's patented CBD cocrystal, which also includes tetramethylpyrazine (TMP), aims to improve bioavailability and efficacy for treating cancer and other conditions. The study was led by Prof. Saoirse O’Sullivan, a scientific advisor to Artelo.
Artelo Biosciences (NASDAQ: ARTL) announced a R&D showcase focused on its Phase 1b/2a Cancer Appetite Recovery Study (CAReS) for lead drug candidate ART27.13. Hosted by Ladenburg Thalmann on July 28, 2021, at 1 PM EDT, the webinar will feature lead investigator Barry Laird, PhD. Key topics include the etiology of anorexia and treatment challenges. Artelo is dedicated to therapeutics targeting lipid signaling pathways, addressing critical needs in diseases like anorexia and cancer. More details can be found on their website.
Artelo Biosciences (ARTL) reported progress in its CAReS study for cancer anorexia, anticipating data by year-end. The company has over $10 million in cash as of May 31, 2021, enabling it to advance key milestones. Despite a net loss of $2.25 million for Q3 2021, up from $951,191 in Q3 2020, Artelo is focused on potential therapies that address significant unmet needs in cancer care. Recent highlights include positive early data for lead candidate ART27.13 and advancements in preclinical assets ART12.11 and ART26.12, targeting cancer treatment.
Artelo Biosciences (NASDAQ: ARTL), a clinical-stage biopharmaceutical company, will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 3:00 p.m. EST. During the virtual event, CEO Gregory D. Gorgas will discuss the company’s focus on therapeutics targeting lipid signaling pathways, particularly the endocannabinoid system. Artelo aims to address significant unmet medical needs across various conditions, including cancer and PTSD. Interested parties can access the presentation via a live webcast.
Artelo Biosciences (NASDAQ: ARTL) announced at the ICRS Symposium that Dr. Andrew Yates will present the ART27.13 Cancer Appetite Recovery Study poster on June 22. This study targets cancer anorexia, a condition affecting over 60% of late-stage cancer patients. Additionally, Prof. Saoirse O’Sullivan will present findings related to Artelo's ART12.11 CBD cocrystal on June 23, highlighting its potential in cancer care. Artelo aims to report initial results from the CAReS trial by Q4 2021, underscoring its focus on innovative therapies in oncology.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the LD Micro Invitational XI, scheduled for June 8-10, 2021. Gregory D. Gorgas, President and CEO, will host a virtual presentation on June 9 at 1:00 p.m. EST. Artelo focuses on developing therapeutics that impact the endocannabinoid system to address unmet medical needs in conditions like cancer and PTSD. For further details and registration, visit the LD Micro Invitational XI event page.
Kintara Therapeutics (Nasdaq: KTRA) announced the appointment of Tamara A. Seymour to its Board of Directors, replacing John Liatos, who remains as Senior VP of Business Development. Seymour, a seasoned finance executive with over 30 years in biotech, has successfully raised over $250 million in equity and debt financing. Under her leadership, Kintara progresses its cancer therapies, VAL-083 and REM-001, targeting glioblastoma and metastatic breast cancer, respectively. The Company aims to address significant unmet medical needs in oncology.
